Based on our finding that KIF15 plays a tumor-promoting role in glioblastoma by accelerating cell cycle progression and P300 HAT activity contributes to the abnormal up-regulation of KIF15 mediated by REST in GBM, we explored and proved the potential of Palbociclib combined with P300 inhibitor (C646) in anti-GBM, which is consistent with our clinical finding that P300/REST/KIF15 axis is positively correlated with the malignant progression of glioblastoma patients. Here, KIF15 is linked to neoplasm.